Wegovy and Ozempic contain the exact same active ingredient, semaglutide, and are made by the same company, Novo Nordisk. They work identically inside your body. But they are not interchangeable. The FDA approved them for different medical conditions, they come in different doses, and insurance treats them very differently.
Same Drug, Different Purpose
The core distinction is what each medication is approved to treat. Ozempic is approved for type 2 diabetes. It helps control blood sugar and is prescribed alongside diet and exercise for people managing that condition. Wegovy is approved for chronic weight management in adults with obesity (a BMI of 30 or higher) or overweight (a BMI of 27 or higher) who also have at least one weight-related health problem.
In March 2024, the FDA also approved Wegovy to reduce the risk of heart attack, stroke, and cardiovascular death in adults who have heart disease along with obesity or overweight. That makes Wegovy the first weight management drug to carry a cardiovascular benefit on its label. Ozempic does not have this approval.
How Semaglutide Works
Both medications mimic a natural gut hormone called GLP-1. When you eat, your body releases this hormone to signal that food has arrived. Semaglutide locks onto the same receptors and amplifies those signals in several ways at once.
It triggers your pancreas to release more insulin, which pulls sugar out of your bloodstream. It blocks glucagon, a hormone that would otherwise push more sugar into circulation. It slows how fast your stomach empties, so glucose from a meal enters your blood more gradually. And it acts on areas of the brain that control hunger, making you feel full sooner and for longer. That combination is why semaglutide lowers blood sugar in people with diabetes and reduces food intake in people using it for weight loss.
The Dosage Difference Matters
Wegovy goes higher. Its maximum maintenance dose is 2.4 mg per week, while Ozempic tops out at 2 mg per week. Both medications start at a low dose and increase gradually over several weeks to reduce side effects, but Wegovy’s final target is 20% higher than Ozempic’s.
That gap in dosing is one reason Wegovy tends to produce more weight loss. A meta-analysis published in the American Journal of Cardiology found that semaglutide at the higher doses used for weight management led to an average loss of about 12% of body weight compared to placebo, translating to roughly 27 pounds. The SUSTAIN trials, which tested semaglutide at the lower diabetes doses, also showed “clinically important” weight loss, but the effect was smaller. Both are injected once a week under the skin, typically in the abdomen, thigh, or upper arm.
Side Effects Are Essentially Identical
Because the active ingredient is the same, Wegovy and Ozempic share the same side effect profile. The most common issues are gastrointestinal: nausea, vomiting, diarrhea, constipation, bloating, gas, heartburn, and stomach pain. These tend to be worst during the dose-escalation phase, when your body is adjusting, and often improve over time.
Nausea is the complaint people report most frequently. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help. The FDA label for both medications warns against using either one alongside any other semaglutide product or similar GLP-1 drug, since stacking them would increase the risk and severity of side effects without added benefit.
Insurance Coverage Is Very Different
This is where the practical gap between the two drugs is widest. Ozempic, as a diabetes medication, is covered by most insurance plans for people with a type 2 diabetes diagnosis. Wegovy, as a weight management drug, faces far more barriers. Most private insurance companies and federal health programs do not cover weight loss medications.
Medicare has been explicitly prohibited by law from covering weight loss treatments since 2003. That means even if your doctor prescribes Wegovy for its cardiovascular benefits, Medicare may not pay for it if the primary indication is weight management. Some patients have lost coverage after their health improved. In one widely reported case, a woman’s pharmacy notified her that Medicare would no longer cover her semaglutide prescription because she no longer qualified as diabetic.
Without insurance, both medications cost over $1,000 per month at retail price. If you have type 2 diabetes, Ozempic is almost always the easier path to coverage. If your goal is weight loss without a diabetes diagnosis, expect to navigate prior authorizations, appeals, or out-of-pocket costs for Wegovy.
Can You Use Ozempic for Weight Loss?
Doctors sometimes prescribe Ozempic “off-label” for weight loss, meaning for a purpose the FDA hasn’t officially approved it for. This happens partly because Ozempic has been available longer and is sometimes easier to get during periods of drug shortages. It contains the same molecule and will produce similar effects on appetite and body weight.
The tradeoff is that Ozempic’s lower maximum dose means you may not achieve the same degree of weight loss you would on Wegovy’s full 2.4 mg dose. You also would not be using a product with the FDA-approved cardiovascular indication that Wegovy carries. And if your insurance is covering Ozempic based on a diabetes diagnosis you don’t have, that creates its own set of complications.
Which One Is Right for You
The choice between Wegovy and Ozempic comes down to your diagnosis and your insurance situation. If you have type 2 diabetes, Ozempic is the straightforward option: it’s approved for your condition, more likely to be covered, and effective for blood sugar control with meaningful weight loss as a bonus. If your primary goal is weight management and you don’t have diabetes, Wegovy is the purpose-built option with a higher dose ceiling and cardiovascular data behind it, but getting it covered will likely be harder and more expensive.
They are, at the molecular level, the same drug. But in the real world of prescriptions, insurance formularies, and FDA labels, they function as two distinct products designed for two distinct patient populations.